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Control of lipid metabolism by adipocyte
FGFR1-mediated adipohepatic communication
during hepatic stress
Chaofeng Yang1, Cong Wang1,6, Min Ye1, Chengliu Jin1,4, Weimin He3,5, Fen Wang1, Wallace L McKeehan1,2
and Yongde Luo1,2*

Abstract
Background: Endocrine FGF19 and FGF21 exert their effects on metabolic homeostasis through fibroblast growth
factor receptor (FGFR) and co-factor betaKlotho (KLB). Ileal FGF19 regulates bile acid metabolism through
specifically FGFR4-KLB in hepatocytes where FGFR1 is not significant. Both FGF19 and FGF21 activate FGFR1-KLB
whose function predominates in adipocytes. Recent studies using administration of FGF19 and FGF21 and genetic
ablation of KLB or adipocyte FGFR1 indicate that FGFR1-KLB mediates the response of adipocytes to both FGF21
and FGF19. Here we show that adipose FGFR1 regulates lipid metabolism through direct effect on adipose tissue
and indirect effects on liver under starvation conditions that cause hepatic stress.
Methods: We employed adipocyte-specific ablations of FGFR1 and FGFR2 genes in mice, and analyzed metabolic
consequences in adipose tissue, liver and systemic parameters under normal, fasting and starvation conditions.
Results: Under normal conditions, the ablation of adipose FGFR1 had little effect on adipocytes, but caused shifts
in expression of hepatic genes involved in lipid metabolism. Starvation conditions precipitated a concurrent
elevation of serum triglycerides and non-esterified fatty acids, and increased hepatic steatosis and adipose lipolysis
in the FGFR1-deficient mice. Little effect on glucose or ketone bodies due to the FGFR1 deficiency was observed.
Conclusions: Our results suggest an adipocyte-hepatocyte communication network mediated by adipocyte FGFR1
that concurrently dampens hepatic lipogenesis and adipocyte lipolysis. We propose that this serves overall to mete
out and extend lipid reserves for neural fuels (glucose and ketone bodies), while at the same time governing extent
of hepatosteatosis during metabolic extremes and other conditions causing hepatic stress.
Keywords: Adipose tissue, Fibroblast growth factor, FGF, Fibroblast growth factor receptor, FGFR, Hepatic steatosis,
Hepatic stress, Lipid metabolism, Starvation

Background
FGF19 (FGF15 in mice) and FGF21 are circulating endocrine factors that affect metabolism and metabolic diseases
including obesity and diabetes [1-4]. FGF19 fluctuates with
normal feeding-fasting cycles and is induced in the ileum
by postprandial bile acids and ligands of the farnesoid X
* Correspondence: yluo@ibt.tamhsc.edu
1
Center for Cancer and Stem Cell Biology, Institute of Biosciences and
Technology, Texas A&M Health Science Center, 2121 W. Holcombe Blvd,
Houston, TX 77030-3303, USA
2
IBT Proteomics and Nanotechnology Laboratory, Institute of Biosciences and
Technology, Texas A&M Health Science Center, 2121 W. Holcombe Blvd,
Houston, TX 77030-3303, USA
Full list of author information is available at the end of the article

receptor (FXR) [5-7]. In contrast, FGF21 is induced in the
liver in response to liver perturbation [8-11] and during
metabolic extremes that include those induced by starvation and obesity [12-14]. Normally hepatic expression
and blood level of FGF21 are low and vary widely among
individuals, but become consistently elevated during
starvation [13].
Genetic deletion experiments have revealed that
FGF19 regulates hepatic cholesterol/bile acid synthesis
specifically through hepatic FGFR4 in partnership with
transmembrane co-receptor KLB [6,15,16]. The direct
tissue target and FGFR isotype that mediate FGF21 action and metabolic effects of FGF19 in addition to

© 2012 Yang et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.

Yang et al. Nutrition & Metabolism 2012, 9:94
http://www.nutritionandmetabolism.com/content/9/1/94

hepatic bile acid metabolism are unclear. Recently we
showed that in addition to FGFR4-KLB, FGF19 also
binds with high affinity and activates FGFR1-KLB
[17,18]. In contrast, FGF21 binds with high affinity and
activates only FGFR1-KLB. FGFR4 is the predominant
FGFR isotype expressed in hepatocytes whereas FGFR1
is expressed at low to negligible levels [18-20]. FGFR1 is
expressed along with KLB prominently in adipocytes
where other FGFRs including FGFR4 are very low or absent [18,19]. In view of the FGFR-KLB binding profile
for FGF19 and FGF21, FGFR1 in adipocytes is a candidate target for FGF21 specifically, while both FGFR1 in
adipocytes and FGFR4 in hepatocytes are targets for
FGF19. Based on response of signal transduction indicators downstream of FGFR, adipose tissue specifically
responds to infusions of FGF21 relative to liver while
both tissues are responsive to FGF19. The responses in
adipocytes were abrogated in mice deficient in adipose
FGFR1 or KLB [18].
Manipulation of expression or pharmacological administration of FGF19 or FGF21 protein in mice has major
impact on metabolic diseases and pathways in hepatocytes in addition to adipocytes [14,21-24]. A collaborative investigation in parallel to this study with our
mouse model deficient in adipose FGFR1 reveals that,
under conditions of diet-induced obesity (DIO) and
FGF21 administration, adipose tissue expressing FGFR1KLB accounts for nearly the entirety of beneficial metabolic effects of FGF21 in vivo a. Under dietary restriction
such as fasting and starvation conditions, FGF21 was
proposed as a starvation hormone and a paracrine factor
acting on liver [13,14]. However, it is unclear whether
the observed metabolic effects in liver under these conditions relative to normal fed state in these two tissues
are a direct consequence of FGF-activated FGFR-KLB
signaling in the respective tissue, or an indirect consequence in the other through systemic inter-organ communication. In this report, we analyzed under normal
and starvation conditions the impact of adipocytespecific deletion of FGFR1 on metabolic parameters
associated with adipose tissue and liver. The deletion
caused little change in adipocyte metabolic gene expression at the transcription level, but instead caused elevation in expression of predominantly lipogenic genes in
the liver. The effects of the adipocyte FGFR1 deficit on
hepatic lipid metabolism were particularly evident under
the metabolic extreme of starvation. From the observations, we conclude that liver is a major indirect response
organ to FGFR1 signaling in adipocytes. Adipocyte
FGFR1 serves to underpin a systemic communication
between hepatocytes and adipocytes mediated by FGF21
production from hepatocytes under stress that signals
through adipose FGFR1. Flux of free fatty acids and adipokines from adipocytes regulated by FGFR1 in turn
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communicates back to liver to limit hepatic lipogenic
gene expression and extent of hepatic steatosis and associated stress. Under these conditions, FGFR1 concurrently dampened lipolytic activity in the adipocytes. We
propose an axis of hepatocyte-adipocyte cooperation
mediated by hepatocyte FGF21 and adipocyte FGFR1
that serves to protect and mete out lipid reserves systemically while protecting the liver against excessive
steatosis and damage under metabolic extremes and
general hepatic stress.

Materials and methods
Animals

The FGFR1-floxed (FGFR1lox/lox, referred to hereafter as
FGFR1Fx or control), FGFR2-floxed (FGFR2Fx) and
aP2-Cre mice have been described [25-27]. These mice
were backcrossed to C57BL/J6 background for more
than 5 generations. Mice with deficiency in FGFR1 and
FGFR2 specifically in adipocytes were generated by crossing the FGFR1Fx and FGFR2Fx mice with aP2-Cre mice
as described (FGFR1lox/loxaP2Cre and FGFR2lox/loxaP2Cre,
referred to hereafter as FGFR1Cn and FGFR2Cn), respectively [18]. Experimental animals were male. The 12 h
fast began at 6:00 PM with 70 percent of the time duration
in dark cycle when murine daily food intake occurs. The
48 h fast began at 6:00 AM when the light cycle started.
All mice were housed in the Program of Animal
Resources in the Institute of Biosciences and Technology,
and were handled in accordance with the principles and
procedure of the Guide for the Care and Use of Laboratory
Animals. All experimental procedures were approved by
the Institute of Biosciences and Technology Institutional
Animal Care and Use Committee (IBT IACUC) with
protocol #10022 entitled “BetaKlotho-FGFR in the liver”
and #09008 entitled “IBT-Mouse Models”.
Analysis of gene expression

Total RNA isolation and quantitative PCR were done as
described [18]. Representative liver tissues were from the
left lobe, and gonadal adipose tissues were used as representative for the adipose tissue, from the number of
mice as indicated.
Cellular fractionation of adipose tissue

Adipocytes were separated from the stromal-vascular
(SV) fraction by a modified Rodbell method [28]. Adenosine was added to suppress lipolysis. About 2 gram
of fat from male mice at ages of eight to ten weeks were
minced into 2–3 mm diameter pieces and dissociated
with 3 mg/ml collagenase in Krebs–Ringer-Hepes (KRH)
buffer [129 mM NaCl, 5 mM NaHCO3, 4.8 mM KCl, 1.2
mM KH2PO4, 1 mM CaCl2, 1.2 mM MgCl2, 2.8 mM
glucose and 10 mM Hepes (pH7.4)], at 37°C with slow
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shaking for 1 h. After filtration through 250 μm gauze
meshes, the adipocyte and SV fractions were separated
by centrifugation at 200 g for 5 min. Adipocytes were
carefully harvested from the top fat cake layer and the
SV fraction was from the pellet on the bottom.
Liver and adipose tissue histology

Portions of freshly isolated liver and adipose tissues were
fixed with Histochoice Tissue Fixative MB (Amresco,
Solon, OH) and paraffin-embedded. Tissue sections were
stained for general pathological examination with
hematoxylin and eosin. In addition, liver tissue was processed in Neg-50 frozen section medium. Lipid droplets
were revealed by staining the frozen section with Oil
Red O at 60°C for 8 min. After washing with 85% isopropanol, the sections were further counterstained with
hematoxylin.
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Serum activities of liver enzymes ALT and AST

The blood samples from FGFR1Fx and FGFR1Cn mice
(n=6 each group) were collected after fed or fasted for
48 h. The activities of liver blood enzymes alanine aminotransferase (ALT) and aspartate aminotransferase
(AST) were measured with an enzymatic activity assay
kit and human based serum calibrator (DC-CAL) (Sekisui diagnostics, Charlottetown, PE Canada).
Statistical analysis

Experiments were reproduced three times independently
with triplicates for each experiment. A representative of
three or more experiments may be shown in micrographs.
Where indicated, the mean and standard deviation (SD) was
determined. Comparisons between different genotype
groups were performed with the unpaired t test. Values were
deemed to be statistically significantly different at p≤0.05.

Serum metabolic parameters and liver lipids

Results

Blood was collected by retro-orbital puncture after
anesthetization with 2,2,2-tribromoethanol (avertin).
Serum was prepared by centrifugation at 2000 g and
stored in aliquots at −80°C. Lipids were extracted from
homogenates of 50 mg tissue with 1 ml chloroform/
methanol (2:1) overnight. After centrifugation at 12000 g
for 15 min, lipids in the lower organic phase were collected and evaporated in a rotary speed vacuum. Lipid
pellets were dissolved in PBS containing 1% Triton X100. Serum parameters were measured with standard
assay kits including triglyceride (TG) (Infinity, Middletown, VA), NEFA and cholesterol (Wako Pure Chemicals, Richmond, VA), and ketone bodies (Stanbio,
Boerne, TX). Serum insulin and glucose levels were
determined by a Glucometer (Bayer, Elkhart, IN).

Ablation of FGFR1 in adipocytes causes changes in
hepatic, but not adipocyte metabolic gene expression

Lipase activity

Gonadal adipose tissue was homogenized in cold lysis
buffer (0.25 M sucrose, 10 mM Tris–HCl, 1 M NaCl, 2
mM EDTA, pH 7.4). Lysate was centrifuged at 10000 x g
for 30 min and the clear aqueous phase was transferred
for analysis. The rate of lipoprotein lipase (LPL) activity
per unit extract protein that hydrolyzes triglycerides
associated with VLDL was measured by an assay kit (Cat
# RB-LPL2, Roar biomedical, Inc., Calverton, NY)
according to the manufacturer’s instructions and rates
determined from the slope of time curves between 20
and 40 min.
Adipokine array

Equal amounts of serum samples from FGFR1Cn or
FGFR1Fx mice under different diet restriction conditions
as indicated, were used to perform antibody array analysis against selected adipokines following the manufacturer’s protocol (R&D Systems, Minneapolis, MN).

Mice deficient in FGFR1 in adipocytes (FGFR1lox/loxaP2Cre
or FGFR1Cn) were generated from mice with the floxed
FGFR1 gene (FGFR1lox/lox or FGFR1Fx) [26] and mice
expressing Cre recombinase driven by the promoter of
adipocyte fatty acid binding protein aP2 [25,29].
LacZ staining in mice with both aP2-Cre+: ROSA26R+
alleles [27] as compared to the control indicated that the
aP2 promoter was active in a majority of adipocytes
(Additional file 1: Figure S1A and B). When compared to
liver, muscle and kidney, the expression of FGFR1 in total
adipose tissue of the FGFR1Cn mice was reduced by 50
percent (Additional file 1: Figure S1C). To determine efficacy of the FGFR1 ablation specifically in the adipocyte
fraction, adipose tissue was fractionated into mature adipocyte and the stromal-vascular (SV) fractions based on
aP2 expression. FGFR1 mRNA in the adipocyte fraction of
the FGFR1Cn mice was reduced to less than 5 percent
that of wildtype or FGFR1lox/lox control mice and to 50
percent in the stromal-vascular fraction (Additional file 1:
Figure S1D). Expression of FGFR2 in mature adipocytes
was unchanged in the FGFR1Cn mice. Expression of cofactor KLB in mature adipocytes was over 15 times that in
the stromal-vascular fraction and was unaffected by the
absence of FGFR1.
The absence of FGFR1 in the adipocytes precipitated
significant changes at the mRNA level in expression of
hepatic genes involved in lipid metabolism. The shifts
predominantly were relative increases in expression of
those associated with lipogenesis (Figure 1A). The
mRNA for membrane fatty acid transporter CD36 was
increased by a dramatic 6 fold accompanied by an increase of 3 fold in the key lipogenic transcriptional regulator PPARγ. Acyl-CoA oxidase (AOX) expression, an
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Figure 1 Effects of adipocyte FGFR1 deficiency on hepatic metabolic gene expression during normal feeding-fasting. Relative expression
of the indicated genes in the liver (Additional file 1: Table S1) involved in lipogenesis (A), fatty acid transport and oxidation (B), gluconeogenesis
and bile acid/cholesterol metabolism (C) and FGF21 transcriptional regulation (D), were assessed by quantitative PCR in control and
adipocyte-deficient FGFR1 mice in normal fed state or after a 4 h fast. Expression in control FGFR1Fx mice was assigned a value of 1. Data
are the mean ± SD of 10 mice with p<0.05 for all tests.

enzyme involved in polyunsaturated fatty acid genesis
and degradation of very long chain FFA, was elevated by
2.5 fold. However, expression of two genes coding for
factors associated with fatty acid oxidation, MTP and
MCAD, was also increased (Figure 1B). No changes were
observed in genes associated with cholesterol/bile acid
metabolism or gluconeogenesis (Figure 1C). Notably, a 3
fold increase in hepatic and systemic FGF21 expression
was observed (Figure 1D, Additional file 1: Figure S2).
This was coincident with significant increases in expression of reported regulators for hepatic FGF21 expression, PPARα and PGC1α [14,23] in response to absence
of adipocyte FGFR1 (Figure 1D).
These adipocyte FGFR1-dependent shifts in hepatic
metabolic gene expression occurred in the absence of
overt changes in body weight, adiposity and morphology
of adipocytes or hepatocytes (Figure 2A-2D), in serum
metabolic parameters including triglycerides, NEFA, glucose and ketone bodies (Additional file 1: Figure S3) and
insulin (not showed), and in expression at the mRNA
level of a variety of genes in adipose tissue that code for
metabolic parameters (Additional file 1: Figure S4). This
indicates that in normal physiology, adipocyte FGFR1
underlies systemic signals from adipocytes to hepatocytes that impact hepatic metabolic gene expression that
is in largest part depression of those involved in
lipogenesis.

The absence of adipocyte FGFR1 results in increase of
starvation-induced hepatic steatosis coincident with
increases in hepatic lipogenic gene expression

No changes in hepatic lipid content or overt hepatocyte
morphology were observed due to the absence of adipocyte FGFR1 under normal feeding conditions. Starvation
is an extreme metabolic condition that imposes stress on
the liver and is evident by development of hepatic steatosis. Under starvation condition, candidate activating
endocrine ligands, FGF21 [13,14] and FGF19 [5,7], are
also induced to sustained elevated levels. Therefore, we
imposed a prolonged 48 h starvation on mice to test for
additional phenotypes in liver, adipose tissue and serum.
The deficit of adipocyte FGFR1 increased the severity of
the hepatic steatosis (Figure 3A). A 1.5 fold increase in
hepatic triglyceride (TG) content coincident (Figure 3B)
with elevation of expression of hepatic genes specifically
involved in lipid metabolism, not glucose or ketone body
metabolism, was also evident in the deficient mice. The
changes in hepatic gene expression due to absence of
adipocyte FGFR1 are still tightly clustered around lipogenic genes similar to observations during normal feeding conditions (Figure 4). Notable differences caused by
the adipocyte FGFR1 deficiency between normal feeding
and the 48 h starvation conditions were elevations of
SREBP1c and SCD1 by 2.5 and 6 fold (Figure 4A), respectively, and lack of increases in fatty acid degradative
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Figure 2 Lack of overt abnormalities in mice lacking adipocyte FGFR1. (A) Change in total body weight (BW) between FGFR1Fx and
FGFR1Cn mice. (B) Change in ratio of gonadal fat to body weight after 4 h fasting and 48 h starvation. (C) Change in body weight loss. (D)
Change in white adipose tissue morphology during 12 and 48 h starved states. Data are the mean ± SD (n=10), p<0.05 for all tests.

factors MTP and MCAD (Figure 4B) and in regulators for
bile acids metabolism and gluconeogenesis (Figure 4C).
The increase of SREBP1c, a fatty liver and hepatic ER
stress marker [30], indicates that an increase of hepatic
stress may accompany the exaggerated lipogenesis and

steatosis caused by the metabolic stress imposed by starvation and adipose FGFR1 deficit. Prolonged starvation
significantly increases hepatic expression of Nrf2 and
Ucp2 but not MnSOD, which are oxidative stress markers;
however, an effect of the adipose FGFR1 deficit was not

Figure 3 Increased starvation-induced fatty liver and lipid content in mice deficient in adipose FGFR1. (A) Appearance of liver tissue.
Conventional hematoxylin and eosin (H&E) staining on liver sections revealed the elevated characteristic vacuoles induced by lipid accumulation.
Staining by Oil Red O revealed an increase in the number and size of lipid droplets. (B) Quantitation of liver TG content. Data are the mean + SD
(n=7-8). **p<0.005, and p<0.05 for all other tests.
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Figure 4 Increase in gene expression of hepatic lipogenic enzymes caused by absence of adipose FGFR1 after starvation. Expression
of the indicated hepatic genes as described in Figure 1 (Additional file 1: Table S1) was assessed by quantitative PCR in control and
adipocyte-deficient FGFR1 mice after food restriction for 48 h. Expression level in FGFR1Fx mice was assigned a value of 1. Data are the
mean ± SD (n= 10), p<0.05 for all tests.

statistically significant (Additional file 1: Figure S5). A lack
of increases in MTP and MCAD in the liver under prolonged starvation is also consistent with the increase of
hepatic lipogenesis and steatosis in the adipose FGFR1
deficient mice. The elevation of PPARα and hepatic
FGF21 mRNAs caused by the loss of adipocyte FGFR1
observed during normal feeding remained intact in the
starvation conditions, while the effect on PGC1α expression and systemic FGF21 was masked or at a maximal level (Figure 4D, Additional file 1: Figure S2).
These results suggest that when liver is under metabolic
stress induced by starvation and steatotic conditions,
adipocyte FGFR1 and its activating ligands underlie signals from adipocytes to hepatocytes that overall dampen
hepatic lipogenic gene expression and limit extent of
starvation-induced hepatic steatosis.
Serum NEFA and triglycerides, but not glucose or ketone
bodies, are concurrently elevated in starved mice
deficient in adipocyte FGFR1

As noted earlier despite shifts in primarily hepatic lipogenic gene expression including systemic FGF21, no
changes in serum NEFA, triglycerides, glucose or ketone
bodies during normal feeding and even after a 24 h fast
could be clearly detected as a consequence of the adipocyte FGFR1 deficiency. However, imposition of the stress
of starvation conditions when hepatic steatosis is apparent caused a detectable rise in serum TG and NEFA
levels at 1.5 and 1.4 fold that of wildtype or FGFR1Fx
mice (Figure 5A and B). In contrast, neither the

depressed glucose levels (Figure 5C) nor elevated ketone
bodies elicited by starvation (Figure 5D) changed between control and deficient mice. These starvationdependent observations on serum parameters elicited by
the adipocyte FGFR1 deficiency are consistent with the
general elevation of specifically hepatic lipogenic genes
and hepatic steatosis, without effect on hepatic genes
involved in glucose and ketone body metabolism. The
forced increase in NEFA level from adipocytes due to
FGFR1 deficit under prolonged starvation, likely in part
resulted in the observed compensatory increases of hepatic and serum FGF21 through hepatic PPARα, and the
elevated hepatic lipogenesis and steatosis as well.
To further quantitatively determine the hepatic stress
level resulting from exaggerated hepatic steatosis due to
the adipose FGFR1 deficiency, we analyzed blood activities of the two liver enzymes alanine aminotransferase
(ALT) and aspartate aminotransferase (AST). Serum
ALT and AST are indicators for pathological changes in
hepatocytes and liver damage/injury and diseases. There
is no significant change in serum activities of ALT and
AST upon adipose FGFR1 deficiency in the normal fed
state. Starvation increases the activities of serum ALT at
about 8% and 22% and AST at about 49% and 80% in
the FGFR1Fx and FGFR1Cn mice, respectively. These
results demonstrate that adipose FGFR1 deficiency significantly elevates the serum enzyme activities of both
ALT and AST, indicating significant exaggeration of liver
stress levels upon adipose FGFR1 deficiency in starvation (Additional file 1: Figure S6).
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Figure 5 Elevated serum TG, NEFA and adipose lipase activity induced by starvation stress in mice deficient in adipocyte FGFR1. (A)
Serum triglycerides, (B) NEFA, (C) glucose and (D) ketone bodies were analyzed in FGFR1Cn and FGFR1Fx mice after food restriction for 12 and
48 h. Data are the mean ± SD (n = 10), ** p<0.005, and p<0.05 for all other tests. (E) Adipocyte total lipase activity. Rate of lipase activity was
assessed by fluorescence as described in Materials and Methods in mice starved for 48 h. Data are the mean ± SD (n = 6).

The adipocyte FGFR1 deficit causes elevated adipocyte
lipase activity during starvation

To determine whether adipocytes participate directly in
the starvation-dependent phenotypic effects of the adipocyte FGFR1 deficiency, we again tested for changes in
adipocyte gene expression. Regulation of expression of
adiponectin by adipose FGFR1 signaling has been
demonstrated a. However, little effect of the adipocyte
FGFR1 deficit on expression of many other metabolic

genes coding for major metabolic enzymes and regulators at the mRNA level, including hsl and atgl, in adipose tissue was observed, similar to normal feeding and
short-term fasting (Additional file 1: Figure S4). Notably,
the rate of lipoprotein lipase enzyme activity in adipocyte extracts from the FGFR1Cn mice was about 1.45
times that of control mice (Figure 5E). The change in
adipose lipase enzyme activity but no effect at the
mRNA level suggested a post-transcriptional regulation
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of lipase activity by adipocyte FGFR1 signaling. This result indicates that under starvation conditions, when an
activating FGF ligand is sufficient, adipocyte FGFR1
serves to dampen lipolysis in the adipocytes while concurrently eliciting signals that dampen lipogenesis and
steatosis in hepatocytes.
Ablation of adipose FGFR2 does not elicit the hepatic
response elicited by the FGFR1 deficiency

FGFR2 is expressed at the mRNA level in adipocytes
and adipose tissue (Additional file 1: Figure S1D). To address whether FGFR2 played a similar role to FGFR1 in
adipose tissue, we prepared a mouse line deficient in adipocyte (FGFR2 FGFR2lox/loxaP2Cre or FGFR2Cn) following the same approach as described for FGFR1. In
agreement with a previous report [31], the FGFR2 deficient mice exhibited no overt abnormalities in development and cellular homeostasis. Moreover, the elevation
in serum TG content and starvation-induced hepatic
steatosis caused by the adipocyte FGFR1 deficiency was
not observed in animals deficient in adipocyte FGFR2
(Figure 6A and B). This indicates that adipocyte FGFR1,
but not FGFR2 underpins the phenotypes in lipid metabolic homeostasis observed in this study.

Discussion
Here we deduce from results of gene ablation, that
under normal dietary condition, FGFR1 in adipocytes
normally underlies signals from adipocytes that restrict
hepatic expression levels of a subset of genes involved in
lipid metabolism. The subset is in largest part genes
associated with hepatic lipogenesis. This occurs without
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apparent changes in adipocyte metabolic gene expression, expression of hepatic genes involved in glucose
metabolism, blood levels of glucose and lipids and
morphology of adipocytes and hepatocytes.
In the presence of transmembrane co-receptor KLB,
both FGF19 and FGF21 bind with high affinity and activate FGFR1 [17,18,20]. In contrast to FGF19, FGF21 fails
to bind and activate FGFR4-KLB that is the predominant
FGFR in hepatocytes. FGF21 is specific for the FGFR1KLB complex which is the predominant FGFR isotype in
adipose tissue [18,20,32]. This differential specificity
limits the direct action of FGF21 to adipose tissue relative to liver, in contrast to the activity of FGF19 which
acts potentially on both adipocytes via FGFR1 and hepatocytes via FGFR4. The activation of adipose tissue by
FGF21 through FGFR1 was suggested by genetic deletion of FGFR1 in adipocytes in mice used in the current
study [18], and this tissue- and molecule-specific actions
of FGF21 underlies the breadth of its in vivo beneficial
effects on treatment of obesity and diabetes a. FGF19 is
a diurnal hormone that fluctuates during normal feeding
[7]. FGF21 comes into play after prolonged periods of
caloric restriction or hepatic perturbation by conditions
such as steatosis or chemical damage [8-14]. This suggests that during normal feeding, ileal FGF19 is likely
the activating endocrine FGF for adipocyte FGFR1. Thus
abrogation of FGF19-adipocyte FGFR1 signaling may
underlie effects of the FGFR1 deficiency on hepatic lipid
gene expression under normal conditions. Such indirect
effects of FGF19 on hepatic lipogenic gene expression
through adipocyte FGFR1-KLB are in addition to the
direct effects on hepatic bile acid [6,15,16] and lipid

Figure 6 FGFR2 deficiency in adipocytes exerted no comparable effect on starvation-induced fatty liver. (A) Histology of liver tissue from
adipocyte-deficient FGFR2 (FGFR2Cn) mice was compared to that from the FGFR1Cn and FGFR2Fx mice in both fed and 48 h starvation states at
two magnifications. The enhanced steatotic vacuolization observed in FGFR1Cn mice was not apparent in the FGFR2Cn mouse livers. (B)
Quantitation of liver TG content from FGFR2Fx and FGFR2Cn mice. Data are the mean ± SD (n= 10), p<0.05 for all other tests.
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metabolism mediated by FGFR4-KLB [9]. The impact of
the changes in hepatic gene expression contributed by
adipocyte FGF19-FGFR1 signaling during normal feeding on the hepatic contribution to overall metabolic
homeostasis remains to be determined. Notably, the deficiency of FGFR1 in adipocytes also caused an increase
in hepatic FGF21 without apparent effect on ileal FGF15
(Yang C, unpublished data). This indicates that during
normal feeding FGF19 working through adipocyte
FGFR1 may suppress expression of hepatic FGF21. This
may be the reason why normally FGF21 levels are low
and variable, and only rise to high sustained levels during severe metabolic extreme as starvation and other
causes of hepatic stress or perturbation.
We used starvation conditions to impose metabolic
stress on the liver that is evident by overt hepatic steatosis. Under these conditions, we observed systemic
and hepatic metabolic consequences due to the adipocyte FGFR1 deficiency. We therefore deduce that
under conditions as starvation that causes severe hepatic stress, the role of adipocyte FGFR1 and its cognate
activating ligands underlies signals that restrict adipocyte lipolysis and through adipocyte to hepatocyte signals concurrently restrict extent of hepatic lipogenesis.
These signals likely include free fatty acids and/or adipokines such as adiponectin, as a result of changes in
lipolysis and endocrine function of adipose tissue governed by adipose FGFR1 signaling. Increased free fatty
acids from adipose tissue deficient in FGFR1 further
enhance the expression of hepatic FGF21 through its
nuclear receptor PPARα, whose expression is also
increased under these conditions that may be due to
change in adiponectin level [33,34]a. Increased free
fatty acids also contribute to exacerbated hepatic steatosis. These results suggest an inter-organ communication between adipose tissue and the liver mediated by
hepatic FGF21 and adipose FGFR1 through adipocyte
signals that include free fatty acids and/or adipokines.
In view of the absence of overt phenotypic effects during normal feeding beyond the changes in hepatic lipid
gene expression, our results suggest that adipocyte
FGFR1 plays its most important physiological role
under metabolic extremes and other conditions that
stress the liver. Such conditions induce sustained and
maximal levels of serum FGF21 [13,14] and FGF19 [5],
and thus are conditions where endocrine activation of
adipocyte FGFR1 would be maximal. We propose that
the phenotypes observed using starvation as a specific
metabolic extreme may reflect a general hepaticadipocyte communication network, which is comprised of hepatic FGF21 induced by general metabolic
or other type of stress on the liver, adipocyte FGFR1
and FGFR1-mediated metabolite and adipokine signals
such as free fatty acids and adiponectin or other yet to
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be identified factors back to the liver (Figure 7). In
addition to starvation, an increase in hepatic FGF21
generally accompanies hepatic stress-inducing conditions of obesity and chemical insult, infection and
inflammation [8-14,35,36]. This communication primarily governed by adipose FGFR1 serves to limit
adipose lipolysis and hepatic steatosis, liver stress and
resultant damage under stressful or adverse conditions.
A hallmark of the starvation-induced signaling axis
from hepatic FGF21 to adipocyte FGFR1 indicated by
our study, is the concurrent changes in adipocyte lipolysis and hepatic lipogenesis partitioned between the two
organs. Under the starvation conditions, the changes in
lipid metabolism also appear relatively independent of
glucose and ketone body metabolism. Normally lipid
metabolism including both lipolysis and lipogenesis is
tightly coupled to glucose and ketone body metabolism
in overall metabolic homeostasis. Moreover, overall lipolysis and lipogenesis are tightly coupled and inversely
related to each other. During the course of starvation,

Figure 7 An adipocyte FGFR1-mediated hepatocyte-adipocyte
communication axis during hepatic stress. Diverse conditions as
the metabolic extremes of starvation, obesity and chemical and
biological insults induce FGF21 that signals the stress to adipocytes.
FGF21 activates adipose FGFR1 signaling to inhibit adipocyte
lipolysis and to activate signals back to the liver that collectively
dampen lipogenesis, steatosis and hepatic stress.
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glucose levels progressively sink. The uncoupling promoted by the hepatocyte-adipocyte axis may serve to
slow down the flow of lipids into glucose and ketone
bodies. This extends critical lipid stores for as long as
possible for maintenance of brain fuels above critically
low levels until feeding resumes. This metabolic uncoupling promoted by the hepatic FGF21-adipocyte FGFR1
axis may be of temporary benefit to the organism under
conditions of not only starvation, but also a variety of
other conditions that are stressful to the liver when overloaded beyond its routine role in metabolic homeostasis.
Reversible hepatic steatosis generally accompanies such
conditions. The endocrine FGF-mediated hepatocyteadipocyte axis may also serve to limit hepatic steatosis
before it becomes irreversibly damaging.

Conclusions
Adipocyte-specific deletion of FGFR isotypes, FGFR1
and FGFR2 show that specifically adipose FGFR1 mediates indirect effects in liver that are most significant
under starvation conditions which causes hepatic stress
and steatosis. This occurs through direct adipose
FGFR1-dependent restrictions on adipocyte lipolysis [37]
and indirectly hepatic lipogenesis through systemic adipocyte to hepatocyte signals. This communication also
serves to attenuate extent of compensatory hepatic steatosis that often occurs during hepatic stress. This adipohepatic communication cycle also serves overall to mete
out and extend lipid reserves for neural fuels (glucose
and ketone bodies) during metabolic extremes and other
conditions causing hepatic stress. This is particularly of
benefit, possibly life-saving, during prolonged starvation
to preserve consciousness until feeding opportunity
occurs. Since adipocyte FGFR1 is a selective target of
FGF21 and an additional target of FGF19 in addition to
hepatocyte FGFR4, our results predict that this
adipocyte-directed mechanism [38,39] may underpin the
beneficial effects of endocrine ligands, FGF21 and
FGF19, observed under conditions of not only caloric restriction, but also excess as in obesity that both cause
metabolic perturbation in the liver.
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Additional file
Additional file 1: Figure S1. Specificity and efficiency of FGFR1 ablation
in adipose tissue using the aP2 promoter. (A) Expression of the aP2
promoter in adipose tissue. The male reproductive complexes with

attached gonadal adipose tissues in LacZ ROSA26R reporter mice
(aP2Cre-) and the reporter mice crossed with aP2Cre mice (aP2Cre+)
were analyzed by LacZ staining (blue). (B) Expression of the aP2 promoter
in adipocytes. A paraffin-embedded section of the LacZ-stained (blue)
gonadal fat tissue from (A) showed that more than 90 percent of
adipocytes were positive for the aP2Cre recombinase activity. Tissue was
counterstained with H&E. (C) FGFR1 mRNA expression among different
tissues in FGFR1Fx and FGFR1Cn mice. FGFR1 expression was assessed
by quantitative PCR. Total white adipose tissue (WAT) exhibited a 50%
reduction of FGFR1 expression in the FGFR1Cn mice. *p<0.05 (n=5). (D)
Relative expression of FGFR1, FGFR2 and KLB in mature adipocyte and
the stromal-vascular (SV) fractions of adipose tissue. a: significant
difference between adipocytes and sv fractions. b: significant difference
between FGFR1Fx and FGFR1 Cn in the same adipocytes fraction or sv
fraction. Data are the mean ± SD (n = 7-8), * p<0.05. Figure S2. Relative
serum levels of FGF21 in the FGFR1Fx and FGFR1Cn mice at fed or fasted
stages. The relative serum levels of FGF21 were measured by adipokine
array kit (R&D systems) according to product manual. Sera were pooled
from 3 mice (50 ul each mouse) for each genotype at fed state or after
starved for 48 h. The dot blot membranes were analyzed for FGF21
antigen levels (A) and the relative intensity of spot was determined by
densitometry (B). Figure S3. Lack of effect of the adipocyte FGFR1
deficiency on serum metabolic parameters in the fed state. Sera were
collected from mice fed ad libitum within one hour after the start of the
light part in the light–dark cycle. Imposed fasting for 4 h yielded similar
results. The indicated parameters were assessed as described in text
Figure 5. Data are the mean ± SD (n= 10), p<0.05 for all tests. Figure S4.
Lack of effect of the adipocyte FGFR1 deficiency on metabolic gene
expression in adipose tissue. Expression of the indicated genes as
described in Additional file 1: Table S1 in FGFR1Fx and FGFR1Cn mice
was assessed by quantitative PCR after 4 h fasting or 48 h starvation. The
expression levels were standardized relative to those of FGFR1Fx mice
with 4 h fasting, which were assigned a value of 1. Data are the mean ±
SD (n= 10), p<0.05 for all tests. Figure S5. Effects of adipose FGFR1
deficiency on the expression of oxidative stress markers Ucp2 and Nrf2.
mRNA levels for hepatic Ucp2 and Nrf2 were determined by quantitative
PCR analyses. The expression level is relative to the FGFR1Fx under
normal fed condition, which is considered as an arbitrary unit 1. Data are
the mean ± SD of 6 mice for each group, p<0.05. Figure S6. Effects of
adipose FGFR1 deficiency on serum enzyme activities for liver ALT and
AST. Blood is collected from FGFR1Fx and FGFR1Cn mice after food
starvation for 48 h, and serum is used to measure enzyme activities of
liver-derived ALT and AST as a result of liver injury and diseases. Data are
the mean ± SD of 6 mice for each group, * p<0.05. Table S1. Metabolic
genes analyzed in expression analyses.
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